Bolt Biotherapeutics (BOLT, Financial) experienced a significant stock price increase of 6.52%, reaching $0.639 per share. The trading volume was 120,559 shares, with a turnover rate of 0.31% and a price fluctuation of 7.97%.
Recent financial reports reveal that Bolt Biotherapeutics generated revenue of $1.14 million, with a net loss of $15.18 million and an earnings per share (EPS) of -$0.40. The company achieved a gross profit of $701,000 and holds a price-to-earnings (P/E) ratio of -0.36. Among the three institutions providing ratings, 100% recommend holding the stock, with no buy or sell recommendations.
Within the broader biotechnology sector, which saw a minor decline of 0.01%, several related stocks showed notable performance. Poseida Therapeutics, Surrozen Inc, and Ocean Biomedical Inc recorded significant gains. Meanwhile, Cassava Sciences, Elevai Labs, and Virpax Pharmaceuticals demonstrated high activity with turnover rates of 56.72%, 51.89%, and 33.62%, respectively. Stocks with considerable price fluctuations included Rocket Pharmaceuticals, Tc Biopharm, and Lakeshore Biopharma, with amplitudes of 85.82%, 57.50%, and 55.39% respectively.
Bolt Biotherapeutics is a clinical-stage immuno-oncology company focusing on tumor-targeted therapies that leverage both the innate and adaptive immune systems. The company's pipeline includes BDC-1001, BDC-3042, and Next-Gen ISAC, built on its proprietary Boltbody ISAC platform technology, which combines tumor-targeting antibodies with immune-stimulating linker-loads.
